| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 15, 2012 | Director | Form 4 | Other acquisition or disposition | -- | -- | 3,000 | |
| Feb 15, 2012 | Director | Form 4 | Other acquisition or disposition | -- | -- | 3,000 | |
| Feb 13, 2012 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,000 | $12.93 | 25,846 | |
| Feb 13, 2012 | Director, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,000 | $12.95 | 31,000 | |
| Feb 02, 2012 | SVP, Business Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,000 | -- | 15,000 | |
| Feb 02, 2012 | SVP, Business Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 80,000 | -- | 80,000 | |
| Jan 12, 2012 | SVP, GM - Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 3,502 | |
| Jan 12, 2012 | SVP, GM - Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 4,000 | |
| Jan 12, 2012 | SVP, GM - Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 3,000 | |
| Jan 12, 2012 | SVP, GM - Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 4,000 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.